Sesen Bio, Inc. (SESN)

NASDAQ: SESN · IEX Real-Time Price · USD
0.688
-0.030 (-4.11%)
At close: Aug 17, 2022 4:00 PM
0.710
+0.022 (3.198%)
After-hours: Aug 17, 2022 5:19 PM EDT
-4.11%
Market Cap 137.23M
Revenue (ttm) 20.00M
Net Income (ttm) 47.80M
Shares Out 199.46M
EPS (ttm) 0.34
PE Ratio 2.02
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,664,753
Open 0.701
Previous Close 0.718
Day's Range 0.681 - 0.737
52-Week Range 0.365 - 1.520
Beta 0.58
Analysts Sell
Price Target 0.82 (+19.2%)
Earnings Date Aug 8, 2022

About SESN

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the tre... [Read more...]

Industry Biotechnology
IPO Date Feb 6, 2014
CEO Thomas Cannell
Employees 35
Stock Exchange NASDAQ
Ticker Symbol SESN
Full Company Profile

Financial Performance

In 2021, Sesen Bio's revenue was $26.54 million, an increase of 136.24% compared to the previous year's $11.24 million. Losses were -$336,000, -98.50% less than in 2020.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for SESN stock is "Sell." The 12-month stock price forecast is 0.82, which is an increase of 19.19% from the latest price.

Price Target
$0.82
(19.19% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Best Momentum Stocks to Buy for August 15th

BRT, ERJ, and SESN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2022.

Other symbols: BRTERJ

Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company paused clinical development of it...

What's in the Cards for Sesen Bio's (SESN) Q2 Earnings?

Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.

Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down

Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.

Why Shares Of Sesen Bio Are Down 28% Today

Sesen Bio Inc (NASDAQ: SESN) shares are trading lower by 28.9% at $0.66 Monday morning after the company announced that it has made the decision to voluntarily pause further development in the US of its...

Sesen Bio Pauses Clinical Development Of Its Lead Bladder Cancer Candidate In US

Based on a thorough reassessment Sesen Bio Inc (NASDAQ: SESN) has decided to voluntarily pause further development in the U.S. of its lead asset, Vicineum, for non-muscle invasive bladder cancer (NMIBC)...

Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today announced that it has made the strategic decision to voluntarily pause further development in the US of its lead asset, Vicineum. The de...

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

Other symbols: ALKSREGNSNY

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sesen Bio, Inc.

Wilmington, Delaware--(Newsfile Corp. - May 18, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Sesen Bio, Inc. (NASDAQ: SESN) on behalf of stockholde...

Sesen Bio Reports First Quarter 2022 Financial Results and Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...

Sesen Bio Provides Strategic Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...

Sesen Bio Further Enhances Team with Key Hires

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the ...

6 of the Best Penny Stocks Under $1 to Buy Now for 2022

These penny stocks trading for under $1 per share all have strong chances of delivering stunning returns in the coming year. The post 6 of the Best Penny Stocks Under $1 to Buy Now for 2022 appeared fir...

Other symbols: DSSJOBSNDLSRGAWTRH

Why Sesen Bio Stock Got Slammed Today

The company's hopeful words about its pipeline drug fell on deaf ears.

Sesen Bio To Conduct Additional Trial For Potential Resubmission Of Vicineum In Bladder Cancer

Sesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with ...

Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced its a...

Are Options Traders Betting on a Big Move in Sesen Bio (SESN) Stock?

Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared f...

7 Penny Stocks with 10x Potential in 2022

Which penny stocks should you watch into 2022? Keep these early-stage companies, fallen angels and turnaround plays on your radar.

Sesen Bio Strengthens Medical Team

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the ...

Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that...

SESEN BIO, INC. (SESN) Reports Q3 Loss, Lags Revenue Estimates

SESEN BIO, INC. (SESN) delivered earnings and revenue surprises of 71.43% and -100.00%, respectively, for the quarter ended September 2021.

Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported opera...

SESEN BIO, INC. (SESN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

SESEN BIO, INC. (SESN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.